The Bull Case For Viking Therapeutics (VKTX) Could Change Following Fresh Validation Of Oral Obesity Drugs

• In recent weeks, analysts reiterated positive views on Viking Therapeutics after competitor Eli Lilly reported supportive Phase 3 results for a similar oral obesity therapy, reinforcing confidence in Viking’s lead candidate VK2735 and its broader metabolic pipeline.
• This combination of bullish analyst coverage and external clinical validation highlights how Viking, still without approved products, is increasingly viewed as a potential participant in large obesity and NASH markets.
• We’ll now examine how this analyst enthusiasm, underpinned by external validation of oral obesity treatments, shapes Viking Therapeutics’ investment narrative.

This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

What Is Viking Therapeutics' Investment Narrative?

To own Viking Therapeutics today, you have to believe its GLP‑1/GIP franchise can convert strong mid‑stage data into successful late‑stage trials and, eventually, commercial products, despite zero revenue and rising losses. The recent wave of bullish analyst commentary following Eli Lilly’s supportive Phase 3 oral obesity data does not change Viking’s core near term catalysts, but it does strengthen confidence around VK2735’s oral program, which had already completed Phase 2 enrollment and shown encouraging weight‑loss signals. In the short run, the key milestones still center on VK2735 and VK2809 readouts and regulatory progress, while the biggest risks remain binary clinical outcomes, sustained cash burn (over US$200,000,000 in recent twelve‑month losses), governance questions such as high CEO pay, and potential dilution if more capital is needed.

However, investors should not overlook how quickly Viking’s cash needs could grow if trials expand. According our valuation report, there's an indication that Viking Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

Twenty‑four Simply Wall St Community valuations span roughly US$9.34 to US$93.39 per share, highlighting very different expectations. Against that wide spread, Viking’s reliance on a few pivotal VK2735 and VK2809 data points means any clinical setback or delay could quickly change how many of those scenarios still feel realistic, so it is worth weighing several viewpoints before deciding how much risk fits your portfolio.

Explore 24 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Build Your Own Viking Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com